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Abstract
Purpose—Cutaneous sclerosis (CS) occurs in 20% of patients with chronic graft-versus-host 
disease (GVHD) and can compromise mobility and quality of life.
Experimental design—We conducted a prospective, multi-center, randomized, two-arm phase 
II crossover trial of imatinib (200 mg daily) or rituximab (375 mg/m2 intravenously weekly × 4 
doses, repeatable after 3 months) for treatment of CS diagnosed within 18 months 
(NCT01309997). The primary endpoint was significant clinical response (SCR) at 6 months, 
defined as quantitative improvement in skin sclerosis or joint range of motion. Treatment success 
was defined as SCR at 6 months without crossover, recurrent malignancy or death. Secondary end 
points included changes of B cell profiles in blood (BAFF levels and cellular subsets), patient-
reported outcomes, and histopathology between responders and non-responders with each therapy.
Results—SCR was observed in 9 of 35 (26%, 95% CI 13-43%) participants randomized to 
imatinib and 10 of 37 (27%, 95% CI 14-44%) randomized to rituximab. Six (17%, 95% CI 7-34%) 
patients in the imatinib arm and 5 (14%, 95% CI 5-29%) in the rituximab arm had treatment 
success. Higher percentages of activated B cells (CD27+) were seen at enrollment in rituximab-
treated patients who had treatment success (p = 0.01), but not in imatinib-treated patients.
Conclusion—These results support the need for more effective therapies for CS and suggest that 
activated B cells define a subgroup of patients with CS who are more likely to respond to 
rituximab.
Keywords
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Introduction
Cutaneous sclerosis (CS) associated with chronic graft-versus-host disease (GVHD) can 
severely affect mobility and quality of life and is a major cause of disability and morbidity 
after allogeneic hematopoietic cell transplantation (HCT). A recent multicenter prospective 
study of 909 HCT recipients reported a 10% 2-year cumulative incidence of CS after HCT 
(1). The 3-year cumulative incidence of CS was 20% among the largest reported 
retrospective study of 977 patients with chronic GVHD (2). Cutaneous sclerosis is often 
refractory to immunosuppressive therapy. Advanced CS causes joint contractures, chronic 
skin ulcers, pulmonary insufficiency due to thoracic encasement, and other disabilities. Risk 
factors for CS among patients with chronic GVHD and the potential impact of CS on 
transplant outcomes have been reported (2-4). Use of a mobilized peripheral blood graft and 
total body irradiation in the transplant conditioning regimen were associated with an 
increased risk of CS (2, 3). No increased risk of overall mortality, nonrelapse mortality or 
recurrent malignancy has been found in patients with CS compared to chronic GVHD 
patients without CS, but the development of CS was associated with longer time to 
withdrawal of immunosuppressive treatment for chronic GVHD (2).
The pathogenesis of CS is not understood. While CS has some clinical and histopathological 
similarities with systemic sclerosis (SSc), some difference are noted. For instance, CS 
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begins in the upper dermal layers and then extends more deeply, whereas SSc begins in the 
deeper skin layer and then extends toward the surface (5). Intimal hyperplasia is seen in both 
chronic GVHD and SSc, but capillary rarefaction and loss of endothelial-specific markers 
were not seen in chronic GVHD as they are in SSc (6). Still, the molecular stimuli for 
fibrosis could be similar in the two diseases.
Stimulatory antibodies against the platelet derived growth factor receptor (PDGFR) have 
been identified in patients with SSc and CS in chronic GVHD (7, 8). This observation has 
served as the rationale for testing imatinib, an inhibitor of signaling through PDGFR, as a 
treatment for CS. Imatinib has been reported to have clinical activity against sclerotic 
chronic GVHD (9-11). Another hypothesis is that dysregulated donor B cell responses result 
in the sclerotic phenotype. Accumulating data suggest high levels of B-cell activating factor 
(BAFF) after allogeneic HCT promote the survival of allo- and auto-reactive B cells and 
cause persistent activation of B cell signaling pathways in chronic GVHD (12, 13). In 
patient B cells and in murine models, inhibition of B cell signaling can prevent or reverse 
tissue injury caused by chronic GVHD (14, 15). Rituximab has broad immunoregulatory 
effects and has shown promising activity in patients with chronic GVHD as a B cell-
depleting therapy (16-19).
In this prospective clinical trial targeting CS associated with chronic GVHD, we tested 
whether imatinib or rituximab could improve the clinical manifestations of CS.
Methods
Participants
Participants were enrolled at 11 institutions within the Chronic GVHD Consortium 
(NCT01309997). The protocol was IRB-approved at each site. Informed consent was 
obtained in accordance with the Declaration of Helsinki. Participants were enrolled in the 
study between March 2011 and June 2014, and the data were analyzed as of January 31, 
2015.
Eligible patients were children or adults diagnosed within the past 18 months with CS after 
allogeneic HCT, with no medication added for the treatment of GVHD within the past 4 
weeks. Participants were receiving corticosteroids at a dose greater than required for 
treatment of adrenal insufficiency unless the physician documented why steroids were 
contraindicated, but documentation of steroid-dependence or –refractoriness was not 
required. CS was defined as sclerotic skin, morphea-like involvement, myofascial 
involvement or joint contractures [a Vienna Skin Score (VSS) ≥2 in any area (20), or 
Photographic Range of Motion (P-ROM) score of 5 or less at the shoulders, elbows, or 
wrists, or a score of 3 or less at the ankles] (21). Exclusion criteria included treatment with 
imatinib within the previous 6 months for any indication, treatment with any monoclonal B-
cell antibody therapy (e.g. rituximab, ofatumumab) within the previous 12 months for any 
indication, and concomitant treatment with extracorporeal photopheresis. Concomitant 
treatment with sirolimus was also not permitted initially because of potential interactions 
with imatinib, but this study exclusion was removed later.
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Study design
The study was designed as a prospective, multi-center, open-label, randomized phase II trial 
of imatinib (200 mg daily by mouth, provided by Novartis) or rituximab (375 mg/m2 
intravenously weekly × 4 doses, repeatable after 3 months, provided by Genentech) for the 
treatment of CS. Randomization was stratified by center and baseline steroid dose (<30 
mg/d vs. >30 mg/d).
The primary objective of the trial was to determine the clinical response rate of CS after 6 
months of initial therapy with either imatinib or rituximab. The primary endpoint was the 
significant clinical response (SCR) rate at 6 months, defined as a 2 or more point 
improvement on the VSS without worsening elsewhere or at least a 1-point improvement in 
the 4 level P-ROM scale or a 2-point improvement in the 7 level scale without worsening 
elsewhere. Crossover to the other study arm was allowed at 6 months if CS did not improve, 
or earlier for CS progression or drug intolerance. CS progression was defined as a 2-point or 
more worsening on the VSS or a 1-point worsening in the 4 level P-ROM scale or a 2-point 
worsening in the 7 level scale, although crossover was also allowed for clinical worsening 
not fulfilling these criteria. Treatment success was defined as SCR at 6 months without 
crossover to the other arm, recurrent malignancy or death.
Secondary endpoints of the study included in this report are the following: (1) the 
cumulative incidence of treatment failure defined as failure to achieve a SCR at the 6 month 
assessment, crossover to the other arm, or stopping initial treatment due to toxicity, (2) the 
proportion of patients able to decrease their daily corticosteroid dose to < 50% of their 
enrollment dose, (3) the proportion of patients with any body surface area (BSA) percentage 
decline in sclerosis without BSA increase in percentage of higher grades of sclerosis 
elsewhere according to the VSS, (4) correlation of changes in patient-reported outcomes 
with response, and (5) correlation of changes in skin biopsy histology and B cell profiles in 
blood (cytokine and cellular subsets) between responders (SCR) and non-responders with 
each therapeutic agent.
Clinician assessments using the VSS (Supplemental Figure 1), P-ROM (Supplemental 
Figure 2) and NIH chronic GVHD consensus conference scoring system (22) and patient 
self-reported outcomes (SHAQ (23, 24), FACT-BMT, Short Form 36 (SF36) (25), Lee 
symptom scale (26), and health activity profile (HAP) (27)) were performed at study 
enrollment and months 3, 6, 9, 12, and 18. Clinicians were also asked to qualitatively rate 
patients' response in skin and joint chronic GVHD at 6 months on an 8 point scale of 
resolved/very much better/moderately better (better), a little better/stable/a little worse 
(stable), and moderately worse/very much worse (worse).
Laboratory correlates
Whole blood samples were drawn into ethylenediaminetetraacetic acid (EDTA) and heparin 
containing tubes at study enrollment and at 6 months after initial randomization to each 
treatment arm or at time of cross over, whichever occurred first. Plasma was separated from 
whole blood cells by centrifugation at 600g and stored at -80°C until first thaw and batch 
testing. Soluble BAFF was measured using a commercially available enzyme-linked 
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immunosorbent assay (ELISA) as previous described (28). Fresh blood in EDTA was 
shipped to the Sarantopoulos laboratory from the study sites and analyzed within 36 hours. 
Whole blood was processed for flow cytometry as previously described using antibodies 
directed at CD3, CD19, and CD27. Lymphocytes were gated by size using forward and side 
scatter criteria. A minimum of 50,000 lymphocytes were collected for all samples to ensure 
adequate subset analysis. Cells were analyzed using BD Canto and Flow Jo 10 analysis 
software.
Histopathology correlates
Two 3 mm skin biopsies were obtained from participants at a leading edge of sclerosis at 
study enrollment and at 6 months after initial randomization to each treatment arm or at time 
of cross over, whichever occurred first. The sites were the same unless there was a clinical 
contraindication. All skin biopsy slides were stained with hematoxylin and eosin (HE). Two 
pathologists (TSH, HMS) concurrently reviewed the slides with a double headed microscope 
blinded to all clinical details including treatment for GVHD to reach a consensus about the 
sclerosis grade from 0-5 according to a previously published scale used to assess regression 
of sclerosis after autologous HCT for systemic sclerosis (29).
Statistical design and analysis
When the study was designed, no preliminary data were available to estimate the response 
rate of CS associated with chronic GVHD using the NIH Consensus Diagnosis Criteria (22). 
Thus, a target enrollment of 74 patients was proposed so that 70 patients could be evaluated 
for the primary endpoint (35 per arm). With 35 patients, the proportion of SCR could be 
estimated within approximately 15% of the actual response rate at 6 months (primary end 
point) after treatment with each agent, based on a 95%confidence interval. Improvement 
would not be expected in the absence of effective therapy. All participants who received 
treatment with imatinib for at least 1 week or at least one dose of rituximab were evaluable 
for the primary endpoint.
Overall responses of CS were assessed by the medical provider using semi-quantitative 
measures (see Supplemental Figures 1 and 2) and by patients using the SHAQ, a validated 
instrument for patients with SSc (23, 24). The response endpoint was calculated at 6 months 
by comparison of baseline and 6 month assessments. True discordance in response 
(improvement in one measure while worsening in the other) was considered progression. 
Cumulative incidences of treatment failure were estimated by standard methods.
Baseline and change scores in patient-reported outcomes, laboratory markers and 
histopathologic grades in skin biopsy samples were compared between treatment arms and 
between subgroups achieving treatment success versus those that did not have treatment 
success in each treatment arm.
Results
Of 72 patients enrolled in this study between March 2011 and June 2014, 35 were 
randomized to imatinib and 37 to rituximab. The patient flow diagram is shown in Figure 1. 
Table 1 displays study participant characteristics. The median age was 56 years (range, 
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19-77), 56% were male, and all had organs other than skin involved with chronic GVHD at 
study enrollment. The median time from chronic GVHD onset to study enrollment was 1 
year (range, 0-3.8 years). The median follow-up among 54 surviving participants is 19.5 
months (range, 5.3 to 47.5 months) from study enrollment.
Safety and adverse events/infections
Adverse events observed for treatment with imatinib or rituximab were similar to those 
reported for treatment of patients with chronic GVHD. The grade 3-5 toxicities reported to 
be possibly, probably or definitely attributed to imatinib or rituximab are shown in the 
Supplemental Table. Most events were infectious in nature, primarily respiratory or skin 
infections, with 2 deaths each in the imatinib and rituximab arms potentially attributable to 
the study drug. All 4 deaths were due to respiratory complications. In the imatinib arm, the 
deaths were caused by aspergillus pneumonia and parainfluenza pneumonia. In the 
rituximab arm, the deaths were caused by Pneumocystis jirovecii pneumonia in a patient 
who was receiving Bactrim prophylaxis, and aspergillus pneumonia. One patient in the 
rituximab arm had a grade 3 infusional toxicity that resolved with additional medication. As 
expected, grade 3-4 neutropenia occurred more frequently in the rituximab arm.
Clinical responses after initial treatment
Disposition of study participants is shown in Figure 1. Of 72 participants, 61 were fully 
evaluable for the primary endpoint after initial randomization (30 in the imatinib arm and 31 
in rituximab treatment arm) based on enrollment and 6 month clinician-reported data. 
Eleven patients did not have 6 month data available for the reasons detailed in Figure 1.
Clinical responses and other outcomes after initial randomization to imatinib or rituximab 
are summarized in Table 2. SCR was observed in 9/35 (26%, 95% CI 13%-43%) 
participants randomized to imatinib and 10/37 (27%, 95% CI 14%-44%) randomized to 
rituximab. Among patients with SCR, 3 in the imatinib arm and 5 in the rituximab arm 
crossed over due to clinician-perceived lack of adequate response despite SCR. In 7 of these 
cases, improvement in one or more areas was recognized, but overall the response of the 
sclerosis was not deemed sufficient to continue on initial treatment. In one case, the patient 
was thought to have a significant clinical response at 6 months but crossed over shortly 
thereafter when sclerosis worsened.
Six (17%, 95% CI 7%-34%) patients in the imatinib arm and 5 (14%, 95% CI 5%-29%) in 
the rituximab arm had treatment success defined as attaining a SCR without crossover, 
relapse or death at 6 months. Of the 35 participants randomized to imatinib, seven 
completed at least 6 months of treatment with imatinib, did not cross over to rituximab and 
remain alive; of these, two patients are continuing treatment with imatinib. Of the 37 
participants randomized to rituximab, 10 completed one or two courses of treatment with 
rituximab, never crossed over to imatinib, and remain alive.
The cumulative incidence of treatment failure defined as less than a SCR at the 6-month 
assessment or discontinuation of randomized treatment due to chronic GVHD progression or 
treatment intolerance within 6 months after initial randomization was 65% (95% CI 
51%-83%) for patients in the imatinib arm and 58% (95% CI 44%-77%) for the rituximab 
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arm (Figure 2). Eleven patients (5 imatinib, 6 rituximab) could not be confirmed as either 
treatment success or treatment failure due to either early withdrawal for reasons other than 
CS progression or treatment intolerance, or lack of 6 month clinician-reported endpoint data.
The proportion of patients at the 6-month visit able to decrease daily corticosteroids dose to 
50% or less than the baseline dose was 26% (7/27) and 29% (9/32) among patients who 
could be evaluated in the imatinib and rituximab arms, respectively. The proportion of all 
patients at the 6-month visit with any percentage BSA decline (improvement) in total 
movable or non-movable sclerosis without increase in the percentage of non-movable 
sclerosis was 47% (14 of 30) in the imatinib arm and 29% (9 of 31) in the rituximab arm. 
The proportion of patients at 6-months with increase (improvement) in the P-ROM in any 
joint without decreased (worsening) in other joints was 13% (4 of 30 evaluable patients) 
with imatinib and was 32% (10 of 31 evaluable patients) with rituximab.
Clinicians' qualitative assessments of skin response at 6 months was 26% better, 52% stable, 
11% worse, and 11% missing in the imatinib arm and 16% better, 54% stable, 16% worse, 
and 14% missing in the rituximab arm. For joints, clinicians reported 17% better, 54% 
stable, 6% worse, and 23% missing in the imatinib arm and 3% better, 73% stable, 3% 
worse and 21% missing in the rituximab arm.
Clinical responses after crossover
Among 18 patients who crossed over to the rituximab arm, 5 experienced a SCR by 6 
months after crossover, 2 have not yet been followed for 6 months, and 11 others either 
withdrew without response (n=2), died (n=1), or did not have a SCR (n=8), for a treatment 
success rate of 5/16 (31%) among those with at least 6 months of follow-up after crossover. 
Among 17 patients who are alive and crossed over to the rituximab treatment arm, 10 
patients have not required new treatment for CS at the time of this analysis. Among 23 
patients who crossed over to the imatinib arm, 4 experienced a SCR by 6 months after 
crossover, 2 have not been followed for 6 months, and 15 did not (4 withdrew without 
response, 2 withdrew due to toxicity, 3 died, 6 did not have a SCR), for a treatment success 
rate of 4/21 (19%) among those with at least 6 months of follow up after crossover. Among 
14 patients who are alive and crossed over to the imatinib arm, 8 have not required new 
treatment for CS and 2 patients continue this treatment at the time of this analysis.
Patient self-reported outcomes
We evaluated whether sclerosis-related symptoms measured by the SHAQ standard 
disability index correlated with severity of cutaneous sclerosis by clinical findings and 
response to study treatment. The SHAQ score did not correlate with the percentage of total 
body surface with movable or non-movable sclerosis using the VSS but did correlate with 
total P-ROM (Spearman correlation coefficient -0.41, p=0.001). Compared to enrollment, 11 
evaluable patients had SHAQ standard disability index decrease by at least 0.2 units which 
is considered a clinically meaningful difference, but improvement in the SHAQ was not 
correlated with treatment success in either arm.
Changes in other patient-reported outcomes were correlated with treatment arms and 
treatment success. The only significant difference at p<0.01 was a median 10 point decrease 
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(range -55 to +25), p=0.001 for the Lee skin symptom scale for the imatinib arm. There 
were no differences in the other Lee subscale scores, the SF-36, FACT-BMT, or HAP for 
the imatinib arm and no statistically significant changes for any of these scales in the 
rituximab arm. The correlation of changes in patient-reported outcomes and treatment 
success were evaluated for 28 patients in the imatinib arm (6 treatment successes) and 23 in 
the rituximab arm (3 treatment successes) with 6 month patient-reported outcomes. 
Treatment success with imatinib was associated with improvement in the SF-36 vitality 
score (6.2 points vs. -3.1 points, p=0.01) and the Lee lung symptom score (5.0 point 
improvement vs. 5.0 point worsening, p=0.005). There were no differences in the other 
patient-reported measures including skin bother, and no differences correlated with 
rituximab treatment successes.
Laboratory and histopathology correlates
B cells play a role in the development of chronic GVHD and CD27+ B cells are 
constitutively activated in patients with this disease (13, 30). For this study a detailed 
analysis of plasma BAFF levels and B-cell phenotype was carried out at time of enrollment 
and 6 months after the initiation of therapy or crossover. Figure 3A shows activated B cell 
percentages (CD27+) at enrollment stratified by patients who had treatment success 
compared to those who did not in the imatinib and rituximab study arms. There was a 
statistically significant (p=0.01) higher percentage of CD27+ B cells at the time of 
enrollment in the rituximab patients who had treatment success (n=3) compared to those 
who did not. The absolute number of B cells was not statistically different amongst all of the 
treatment arms, but the power of the analysis in the rituximab arm was very limited due to 
sample size (supplemental figure 3). Figure 3B provides representative flow cytometry 
analyses for the rituximab arm responders and non-responders. Cells were initially gated for 
CD19 positivity, and from this population CD27 positive cells were plotted by granularity 
(side scatter). BAFF levels at time of enrollment were similar amongst the treatment arms 
(Supplemental Figure 4), and were not correlated with steroid use in univariate analysis.
At enrollment, the median histopathologic sclerosis score was 2 (range 0-5) in both the 
imatinib arm (n=32) and the rituximab arm (n=31) participants with evaluable biopsies. 
Histopathological grading of sclerosis at enrollment was higher in the 6 patients who had 
treatment success with imatinib compared to the 22 who did not (3.5 vs. 1.4, p=0.001). 
There was no difference in sclerosis histopathologic grade at enrollment in the 4 patients 
with treatment success on rituximab arm compared to the 22 who did not. Treatment success 
was not correlated with change in the sclerosis grade on the post-treatment biopsies in either 
treatment arm although numbers for analysis are very limited because of missing post 
treatment biopsies.
Discussion
Management of CS chronic GVHD is difficult (31, 32), with evidence limited to reports 
from uncontrolled single-arm studies of second-line or subsequent treatments (10, 11, 17, 
33, 34), retrospective studies (19, 35), or reviews (36, 37). In the absence of a definitive 
understanding of the pathophysiologic mechanisms for development of CS, new treatments 
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have relied on empirical testing of agents approved for other indications where 
inflammation, abnormal immune regulation or fibrosis have been implicated as pathogenic 
mechanisms.
We embarked on this study in order to estimate the efficacy of imatinib and rituximab in 
parallel arms in a multicenter study. The current study applied stringent, semi-quantitative 
metrics for the assessments of skin thickness and range of motion to evaluate success of 
either treatment at 6 months. The rates of SCR and treatment success were low (≤27% and 
≤17%, respectively) at 6 months after initial treatment of CS with either imatinib or 
rituximab. Our definitions of SCR were purposefully conservative to try to minimize 
observer bias and increase reliability, but we acknowledge that the clinical meaningfulness 
of these changes has not been established. It is possible that assessments after a longer 
duration of treatment could have shown higher response rates. The study was not designed 
to make direct comparisons between the study arms.
The rates of SCR and treatment success observed in this study are certainly lower than 
reported for these individual agents in the treatment of steroid-refractory chronic GVHD in 
other studies (9, 10, 17, 33, 34), and reviewed in (36, 37). Response measures for CS 
chronic GVHD have not been established (38). The 2005 NIH composite 0-3 skin score and 
the Lee skin symptom score are sensitive measures for clinical monitoring of patients with 
any cutaneous manifestations of chronic GVHD, but these measures were not designed to 
assess response specifically for CS chronic GVHD (39). Thus, the use of more stringent 
response measures could have, in part, accounted for the low response and success rates in 
our study, although response rates measured by clinicians' qualitative assessments were also 
low.
Reported overall responses (complete plus/or partial responses) at 6 months with imatinib 
for treatment of CS were 79%, 36%, and 33% in three single-arm prospective studies (10, 
11, 33), and 50% (95% CI 24% - 76%) response at an unspecified time point in one 
retrospective study (35). The 79% response rate among the 19 total patients in the study by 
Olivieri et al. (10) included 11 patients who received or continued to receive treatment with 
extracorporeal photopheresis (ECP). In contrast, in our study, patients were not treated with 
ECP. The wide variation of overall response rates with imatinib between prior reports and 
our study may also be explained by the semi-quantitative assessment tools used in our study 
to evaluate SC (VSS scale and the P-ROM scale) compared to other tools used in previous 
reports (i.e., Hopkins score (40), NIH diagnostic score (22), and quantitative range of 
motion measures (11)).
Several retrospective and relatively small prospective studies have reported benefits of 
treatment with rituximab in steroid-refractory chronic GVHD (17, 19, 41). Overall response 
rates in the skin, including CS, during treatment with rituximab have ranged from 13% to 
100% as reported in a large prospective study of 37 patients (34) and from a meta-analysis 
(36) that included 111 patients from 3 prospective and 4 retrospective studies. Time and 
criteria for responses varied or were not clearly defined in most studies, making it 
impossible to compare results with our study.
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Reporting of results in chronic GVHD treatment studies has been plagued by poor definition 
of sustainable responses. Results are often interpreted under the premise that no response 
would have occurred in the absence of the treatment being tested, when in fact, other factors 
that might have affected outcomes (31, 38), such as steroid dosing which was not controlled. 
In our study, it is possible that initial therapy may have contributed to eventual treatment 
success after crossover so these results should be interpreted with caution. Although the 
same definitions were applied in assessing responses after the crossover, we noted a trend of 
less treatment failure, suggesting that responses other than SCR at 6 months can evolve to be 
successes with longer follow up. No widely accepted gold standard is currently available for 
determining activity of chronic GVHD or the response to treatment.
We administered a variety of patient-reported measures to evaluate outcomes and found that 
only the Lee skin symptom score improved in the 29 patients who completed the 6 months 
of therapy in the imatinib arm. In particular, the SHAQ, a scleroderma-specific measure that 
focuses on functional abilities, did not correlate with severity of sclerosis as measured by the 
VSS but it did with the P-ROM. The Lee Symptom Scale does include a question about how 
bothered the patient is by thickened skin. Our results suggest that better patient-reported 
measures are needed to capture the impact of CS on quality of life and functioning.
The correlation between high initial CD27+ B cell proportions and treatment success 
observed in the rituximab treatment arm in our study but not in the imatinib arm, suggests 
that rituximab affects activated B cells in CS. Although the number of analyzed cases is 
small, this finding adds further evidence for the role of B cells in the pathogenesis of 
sclerosis in chronic GVHD.
Our results highlight the importance of conducting larger multicenter studies to evaluate 
promising results from smaller studies. Although our different study design, including the 
potential crossover and the use of more stringent response measures may explain the low 
rates of SCR and treatment success in the current study, our results were not nearly as 
encouraging as previous studies. Participants in our trial had significant CS, did not receive 
concomitant treatment with ECP during the study, and most had already been treated with 
frequently used chronic GVHD treatments. Longer-term follow up is necessary to determine 
whether success rates increase with treatment continued beyond 6 months, since changes in 
sclerotic GVHD reverse slowly. However, in this prospective, multicenter study, the 
treatment success rates were low enough to show that more effective therapies for CS are 
clearly needed.
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Translational relevance
Chronic graft-versus-host disease (GVHD) is a syndrome in which the contributions of 
inflammation, innate and adaptive cell-mediated immunity, humoral immunity, abnormal 
immune regulation and fibrosis vary from one patient to the next. Cutaneous sclerosis 
(CS) is a form of chronic GVHD where fibrosis of skin and fascia predominate. In this 
multi-center, randomized, two-arm, phase II crossover trial of imatinib or rituximab for 
CS, there was a statistically significant (p=0.01) higher percentage of activated B cells 
(CD27+) prior to treatment in the rituximab patients who had treatment success compared 
to those who did not, suggesting that activated B cells may be a good marker for patients 
with CS who will respond to rituximab. This relationship was not seen in imatinib-treated 
patients. Although the number of analyzed cases is small, this finding adds further 
evidence for the role of B cells in the pathogenesis of sclerosis in chronic GVHD.
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Figure 1. 
Disposition of trial participants.
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Figure 2. 
Cumulative incidence of treatment failure defined as discontinuation of randomized 
treatment due to chronic GVHD progression or treatment intolerance within 6 months after 
initial randomization or less than a significant clinical response at the 6-month assessment 
according to treatment arm.
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Figure 3. Proportion of CD27+ B-cells at enrollment across treatment groups
A Percentage of CD27+ cells of the CD19+ parent gate in patients who later had treatment 
sucess (responder) or did not (non-responder) to either imatinib or rituximab. B. 
Representative flow cytometry showing baseline CD27 expression of CD19+ (CD3-) B 
cells.
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Table 1
Participant characteristics according to randomization
Characteristic All patients (n = 72)
Initial treatment
Imatinib (n = 35) Rituximab (n = 37)
Patient age, median (range) 56 (19-77) 56 (19-72) 56 (21-78)
Male patient, n (%) 40 (56) 18 (51) 22 (59)
Female donor to male recipient, n (%) 15 (21) 7 (20) 8 (22)
Advanced (high-risk) disease at transplantation, n (%) 16 (22) 9 (26) 7 (19)
Conditioning regimen, n (%)
 Myeloablative 41 (57) 26 (74) 15 (41)
 Reduced intensity or non-myeloablative 31 (43) 9 (26) 22 (59)
Graft source, n (%)
 Mobilized blood cells 67 (94) 32 (94) 35 (95)
 Bone marrow 3 (4) 1 (3) 2 (5)
 Cord blood 1 (1) 1 (3) 0 (0)
Donor type, n (%)
 HLA-fully matched related 24 (33) 15 (43) 9 (24)
 HLA-fully matched unrelated 36 (50) 12 (34) 24 (65)
 HLA-mismatched related or unrelated 12 (17) 8 (23) 4 (11)
Time from transplantation to chronic GVHD, median (range), months 11 (0.4-82) 11 (0.7-82) 11 (0.4-44)
Time from transplant to study enrollment, median (range), months 29 (8-87) 31 (8-87) 27 (14-61)
Presence of GVHD sites involved at enrollment, n (%)
 Skin 70 (99) 34 (100) 36 (97)
 Eyes 47 (65) 21 (60) 26 (70)
 Mouth 39 (54) 20 (57) 19 (51)
 Liver 23 (44) 11 (46) 12 (43)
 Gastrointestinal tract 19 (26) 10 (29) 9 (24)
 Lung 26 (37) 11 (31) 15 (42)
 Joint or fascia 65 (90) 31 (89) 34 (92)
 Genital tract 11 (16) 7 (20) 4 (11)
NIH global score at study enrollment, n (%)
 Moderate 19 (26) 11 (31) 8 (22)
 Severe 53 (74) 24 (69) 29 (78)
Subcategory of chronic GVHD at enrollment, n (%)
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Characteristic All patients (n = 72)
Initial treatment
Imatinib (n = 35) Rituximab (n = 37)
 Classic 14 (19) 8 (23) 6 (16)
 Overlap 58 (81) 27 (77) 31 (84)
Karnofsky score <80% at study enrollment, n (%) 30 (44) 14 (42) 16 (46)
Prior grades II-IV acute GVHD, n (%) 31 (46) 17 (55) 14 (39)
Prednisone dose at study enrollment, n (%)
 None 8 (12) 6 (19) 2 (6)
 <0.5 mg/kg daily 43 (64) 18 (58) 25 (69)
 ≥0.5 mg/kg daily 16 (24) 7 (23) 9 (25)
Other treatment of chronic GVHD at enrollment, n (%)
 Calcineurin inhibitor 36 (50) 19 (54) 17 (46)
 Sirolimus 7 (10) 2 (6) 5 (14)
 Mycophenolatemofetil 6 (8) 4 (11) 2 (5)
 Others† 29 (40) 14 (40) 15 (41)
Number of agents plus initial randomized agent, n (%)
 2 65 (90) 30 (86) 35 (95)
 ≥3 7 (10) 5 (14) 2 (5)
Time from onset of sclerosis to enrollment, median months (interquartile 
range) 1.8 (0.5-5.7) 1.6 (0.2-6.1) 2.3 (0.6-4.1)
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Table 2
Summary of overall clinical results
Outcome
Initial Randomization
Imatinib n = 35 Rituximab n = 37
Significant clinical response, n (%) 9 (26) 10 (27)
 – Treatment success: significant clinical response without crossover, relapse or death at 6 months 6 (17) 5 (14)
Treatment failure at 6 months, n 29 32
 – No significant clinical response§, n 21 21
 – Crossover to other arm§, n 18 23
 – Not evaluable*, n 5 6
§
Totals > 100% because reasons are not mutually exclusive.
*See disposition of study participants shown in Figure 1.
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